Analysts forecast that Keryx Biopharmaceuticals (NASDAQ:KERX) will report earnings of ($0.18) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Keryx Biopharmaceuticals’ earnings, with estimates ranging from ($0.20) to ($0.16). Keryx Biopharmaceuticals posted earnings of ($0.32) per share in the same quarter last year, which would suggest a positive year over year growth rate of 43.8%. The business is scheduled to issue its next earnings report on Wednesday, March 7th.
On average, analysts expect that Keryx Biopharmaceuticals will report full-year earnings of ($1.35) per share for the current financial year, with EPS estimates ranging from ($1.37) to ($1.33). For the next fiscal year, analysts forecast that the business will report earnings of ($0.50) per share, with EPS estimates ranging from ($0.59) to ($0.37). Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Keryx Biopharmaceuticals.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.03). The business had revenue of $15.00 million during the quarter, compared to analyst estimates of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 156.70% and a negative return on equity of 544.63%. Keryx Biopharmaceuticals’s revenue was up 138.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.39) earnings per share.
A number of analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 14th. ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Finally, Stifel Nicolaus lowered their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. Keryx Biopharmaceuticals currently has an average rating of “Hold” and an average price target of $7.35.
A number of institutional investors and hedge funds have recently modified their holdings of KERX. Fox Run Management L.L.C. purchased a new position in Keryx Biopharmaceuticals in the 3rd quarter worth about $101,000. Engineers Gate Manager LP acquired a new stake in Keryx Biopharmaceuticals during the 3rd quarter worth about $102,000. Principal Financial Group Inc. lifted its holdings in shares of Keryx Biopharmaceuticals by 4.2% during the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 590 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Keryx Biopharmaceuticals by 51.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 5,628 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Keryx Biopharmaceuticals during the 2nd quarter valued at about $183,000. 64.82% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Keryx Biopharmaceuticals (KERX) traded up $0.16 during midday trading on Monday, reaching $4.75. 1,295,900 shares of the company were exchanged, compared to its average volume of 1,119,443. The firm has a market cap of $563.47, a PE ratio of -3.17 and a beta of 4.92. Keryx Biopharmaceuticals has a 12-month low of $4.33 and a 12-month high of $8.38. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46.
TRADEMARK VIOLATION WARNING: “Keryx Biopharmaceuticals (KERX) Expected to Announce Earnings of -$0.18 Per Share” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/11/keryx-biopharmaceuticals-kerx-expected-to-announce-earnings-of-0-18-per-share.html.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.